__NUXT_JSONP__("/drugs/Tegavivint", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1227637-23-1",chebiId:b,chemicalFormula:b,definition:"A small molecule inhibitor of the Wnt\u002Fbeta-catenin pathway with potential antineoplastic activity. Upon intravenous administration, tegavivint binds to transducin beta-like protein 1 (TBL1) and disrupts the binding of beta-catenin to TBL1. This promotes beta-catenin degradation, attenuates nuclear and cytoplasmic levels of beta-catenin, and reduces transcriptional activity of transcription factor 4 (TCF4) and expression of its target genes, cyclin D1, c-Myc and survivin. The Wnt\u002Fbeta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.",fdaUniiCode:"18AP231HUP",identifier:"C155885",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C2189"],synonyms:["9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-","BC 2059","BC-2059","BC2059","TEGAVIVINT","Tegatrabetan",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FTegavivint",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Tegavivint","","2021-10-30T13:34:15.103Z")));